Progress on low-dose rituximab for systemic lupus erythematosus / 中华全科医师杂志

ABSTRACT

As a targeted immunosuppressive drug,rituximab is commonly used in the treatment of lymphoma.Recently,its efficacy in the treatment of rheumatic diseases has been concerned.However,studies have found that the dosage of rituximab for systemic lupus erythematosis (SLE) simply followed that for B-cell lymphoma may lead to increased infection risk.This article reviews the clinical application of lowdose rituximab in treatment of SLE with refractory thrombocytopenia,thrombotic thrombocytopenic purpura,lupus nephritis or neuropsychiatric lupus,which suggests that the low-dose rituximab has achieved satisfactory efficacy with good safety and tolerability.